Evidence map›Paper›PMID 30569175›Full record

ArticleInternational journal of molecular medicine2019

Investigation of the neuroprotective effects of crocin via antioxidant activities in HT22 cells and in mice with Alzheimer's disease.

Chunyue Wang, Xueying Cai, Wenji Hu, Zhiping Li, Fange Kong, Xia Chen, Di Wang

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 68 papers.

0numbers the graph read from it
0cells of the map it votes in
68citing papers in PubMed
3.4field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

68 citing papers in PubMed, 128 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Review
  19. Review
  20. Article

8 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Chunyue WangDepartment of Microbiology and Biochemistry, School of Life Sciences, Jilin University, Changchun, Jilin 130012, P.R. China.
Xueying CaiDepartment of Microbiology and Biochemistry, School of Life Sciences, Jilin University, Changchun, Jilin 130012, P.R. China.
Wenji HuDepartment of Microbiology and Biochemistry, School of Life Sciences, Jilin University, Changchun, Jilin 130012, P.R. China.
Zhiping LiDepartment of Pharmacology, College of Basic Medical Sciences, Jilin University, Changchun, Jilin 130006, P.R. China.
Fange KongDepartment of Microbiology and Biochemistry, School of Life Sciences, Jilin University, Changchun, Jilin 130012, P.R. China.
Xia ChenDepartment of Microbiology and Biochemistry, School of Life Sciences, Jilin University, Changchun, Jilin 130012, P.R. China.
Di WangDepartment of Microbiology and Biochemistry, School of Life Sciences, Jilin University, Changchun, Jilin 130012, P.R. China.
Jilin University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Due to its complex pathogenesis, the prevention and therapization of Alzheimer's disease (AD) remains a serious challenge. Crocin, the main compound isolated from Crocus sativus L., demonstrates various pharmacological activities including anti‑apoptotic properties. The present study investigated the neuroprotective effect of crocin and the underlying mechanisms. In l‑glutamate‑damaged HT22 cells, 3‑h crocin pretreatment strongly enhanced the HT22 cell viability, reduced the apoptotic rate, mitigated mitochondrial dysfunction, suppressed intracellular reactive oxygen species (ROS) accumulation and Ca2+ overload compared with untreated cells. Additionally, crocin significantly decreased the expression levels of Bax, Bad and cleaved caspase‑3 and increased the expression levels of B‑cell lymphoma‑extra large, phosphorylated (P‑) protein kinase B and P‑mammalian target of rapamycin compared with untreated cells. In mice with AD induced by d‑galactose and aluminum trichloride, crocin substantially improved the cognition and memory abilities of the mice as measured by their coordination of movement in an open field test, and reduced their escape time in the Morris water maze test compared with untreated mice. Biochemical analysis confirmed that crocin was able to reduce the Aβ1‑42 content in the mouse brains, increase the levels of glutathione peroxidase, superoxide dismutase, acetylcholine and choline acetyltransferase, and reduce the levels of ROS and acetylcholinesterase in the serum, cerebral cortex and hypothalamus compared with untreated mice. Immunohistochemical analysis demonstrated that crocin reduced Aβ1‑42 deposition in the hippocampus of the brains of treated mice compared with untreated mice. In conclusion, crocin demonstrates good prospects in the treatment of AD through the oxidative stress‑associated apoptosis signaling pathway.

Indexed as

Alzheimer DiseaseAnimalsAntioxidantsApoptosisCalciumCarotenoidsCell LineCell SurvivalCognitionDisease Models, AnimalGlutamic AcidMiceMitochondriaNeuroprotective AgentsOxidative StressPyramidal CellsAntioxidantsCalciumCarotenoidscrocinGlutamic AcidNeuroprotective AgentsReactive Oxygen Species

Identifiers

PMID30569175
PMCPMC6317678
OpenAlexW2904566143

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.